Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,076–4,100 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
· Int J Mol Med · 2009 · PMID 19513541 · validated civic_curation pubmed
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
· Int J Cancer · 2012 · PMID 21732342 · validated civic_curation pubmed
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
· Int J Cancer · 2009 · PMID 19035443 · validated civic_curation pubmed
Characteristics of lung cancers harboring NRAS mutations.
· Clin Cancer Res · 2013 · PMID 23515407 · validated civic_curation pubmed
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
· Cancer Res · 2008 · PMID 18632602 · validated civic_curation pubmed
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
· Proc Natl Acad Sci U S A · 2005 · PMID 16046538 · validated civic_curation pubmed
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
· Future Oncol · 2015 · PMID 26161928 · validated civic_curation pubmed

Showing 4,076–4,100 of 4,399 publications

← Previous
1
…
163
164
165
…
176
Next →

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.

· Oncogene · 2011 · PMID 21132006 · validated civic_curation pubmed

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

· Leukemia · 2016 · PMID 26582647 · validated civic_curation pubmed

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

· Oncotarget · 2017 · PMID 29156677 · validated civic_curation pubmed

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.

· PLoS One · 2017 · PMID 28672024 · validated civic_curation pubmed

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

· Blood · 2012 · PMID 23175662 · validated civic_curation pubmed

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.

· Clin Cancer Res · 2018 · PMID 29588308 · validated civic_curation pubmed

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

· Cell · 2016 · PMID 27667683 · validated civic_curation pubmed

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.

· Clin Cancer Res · 2017 · PMID 28637688 · validated civic_curation pubmed

High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.

· Clin Cancer Res · 2022 · PMID 34593528 · validated civic_curation pubmed

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

· Clin Cancer Res · 2014 · PMID 24963049 · validated civic_curation pubmed

Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.

· Cell Death Discov · 2024 · PMID 38461159 · validated civic_curation pubmed

Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

· Cell Death Dis · 2021 · PMID 34247201 · validated civic_curation pubmed

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.

· Nat Genet · 2025 · PMID 41361008 · validated civic_curation pubmed

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

· Cancer Cell · 2010 · PMID 20609353 · validated civic_curation pubmed

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.

· PLoS One · 2015 · PMID 26709701 · validated civic_curation pubmed

In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.

· Anticancer Res · 2015 · PMID 25550549 · validated civic_curation pubmed

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

· Melanoma Res · 2014 · PMID 24950457 · validated civic_curation pubmed